Arpeggio Bio
Arpeggio Bio, based in Boulder, CO, specializes in drug discovery targeting transcription factors with AI and RNA-sequencing technologies. The company, with a team of 20, collaborates with industry giants like J&J and FORMA, focusing on diseases such as IO-resistant melanoma and rare genetic disorders.
Company Overview
Arpeggio Bio, formerly known as Arpeggio Biosciences, is based in Boulder, CO, USA. The company operates in the drug discovery and delivery sub-industry of healthcare. Arpeggio Bio specializes in developing drugs that target transcription factors using artificial intelligence and high-throughput RNA-sequencing technologies. The company has secured $20M in venture funding and is a part of the Y-Combinator S19 batch. With a team size of 20, Arpeggio Bio focuses on biopharma innovations aimed at previously 'undruggable' proteins.
Drug Development and Pipeline
Arpeggio Bio is known for its pipeline targeting challenging proteins such as NRF2, TEAD, and GPX4. The company's lead program is advancing towards a DC for treating IO-resistant melanoma. Additionally, Arpeggio Bio targets Clear Cell Sarcomas, NF2-mutant/YAP-Fusion Cancers, KEAP1-mutant Lung Cancers, and MCTO (Rare Disease). They utilize nascent RNA sequencing to measure RNAs directly affected by compound treatments and have built the largest database of nascent RNA sequences. This aids in linking compound structure-activity relationships with RNA fingerprints.
Strategic Partnerships and Collaborations
Arpeggio Bio collaborates with several key industry players. Notable partnerships include Johnson & Johnson and FORMA Therapeutics. They work with Intrinsic Medicine for drug co-development and Treventis Corporation for target discovery. Moreover, in collaboration with Forma Therapeutics, Arpeggio Bio has leveraged their transcriptional platform to uncover new mechanisms of CBP inhibitors. Together, these partnerships enhance Arpeggio Bio's capabilities in drug discovery and delivery.
Funding and Financial Backing
Arpeggio Bio has successfully raised significant funding to support its research and development endeavors. The company secured $17M in Series A funding led by Builders VC. In total, Arpeggio Bio has amassed $20M in venture funding, enabling them to advance their drug development programs and expand their research capabilities.
Recognition and Achievements
Arpeggio Bio was named a finalist for the Rising Star of the Year Award by the Colorado BioScience Association in October 2023. At the AACR 2023, the company presented two posters demonstrating how high-throughput transcriptomics aids in identifying novel GPX4 inhibitors. Arpeggio Bio's platform has also been validated in rare disease and inflammation, achieving a significant Phase I success. These recognitions underscore the company's contributions and progress in the healthcare industry.